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Edited by Roberto SitiaAbstract The ﬁeld of endoplasmic reticulum (ER) stress in
mammalian cells has expanded rapidly during the past decade,
contributing to understanding of the molecular pathways that al-
low cells to adapt to perturbations in ER homeostasis. One ma-
jor mechanism is mediated by molecular ER chaperones which
are critical not only for quality control of proteins processed in
the ER, but also for regulation of ER signaling in response to
ER stress. Here, we summarized the properties and functions
of GRP78/BiP, GRP94/gp96, GRP170/ORP150, GRP58/
ERp57, PDI, ERp72, calnexin, calreticulin, EDEM, Herp and
co-chaperones SIL1 and P58IPK and their role in development
and diseases. Many of the new insights are derived from recently
constructed mouse models where the genes encoding the chaper-
ones are genetically altered, providing invaluable tools for exam-
ining the physiological involvement of the ER chaperones in vivo.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The endoplasmic reticulum (ER) is an essential cellular com-
partment for protein synthesis and maturation. It also func-
tions as a Ca2+ storage organelle and resource of calcium
signals. The perturbation of ER functions, such as disruption
of Ca2+ homeostasis, inhibition of protein glycosylation or
disulﬁde bond formation, hypoxia and virus or bacteria infec-
tion, can result in accumulation of unfolded or misfolded pro-
teins and the failure of the ER to cope with the excessive
protein load. This leads to ER stress, which is deﬁned as an
imbalance between the cellular demand for ER function and
ER capacity. To reduce the excessive protein loading, the cells
trigger the unfolded protein response (UPR), which signals
transient attenuation of protein translation, degradation of
malfolded proteins and the induction of molecular chaperonesAbbreviations: ER, endoplasmic reticulum; ERAD, ER-associated
degradation; HHcy, hyperhomocysteinemia; PDI, protein disulﬁde
isomerase; PrPsc, scrapie-associated PrP; STEC, Shiga toxigenic
Escherichia coli; SubAB, AB5 subtilase cytotoxin; UPR, unfolded
protein response
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doi:10.1016/j.febslet.2007.04.045and folding enzymes to augment the ER capacity of protein
folding and degradation. However, if the ER stress cannot
be relieved, apoptotic pathways are activated in the damaged
cells. The ER contains a number of molecular chaperones
physiologically involved in the post-translational modiﬁcation,
disulﬁde bond formation, folding, assembly and quality con-
trol of newly synthesized proteins to preserve cellular homeo-
stasis. Upon ER stress, upregulation of ER chaperones is
pivotal for cell survival by facilitating the correct folding and
assembly of ER proteins and preventing their aggregation.
Furthermore, speciﬁc chaperones are also involved in stress
signaling regulation and protein degradation process to atten-
uate apoptotic stimuli. While the link between molecular chap-
erones and human diseases awaits direct proof in most cases,
recent construction and characterization of novel mouse mod-
els where the gene encoding for the ER chaperone protein is
deleted or genetically altered provide new insights on the phys-
iological contribution of these proteins in vivo. This review
highlights recent progress in understanding the role of ER
chaperones in response to ER stress and their functional roles
in mammalian development and human diseases.2. Chaperoning function of ER proteins
The ER chaperones can be categorized into three groups: (a)
chaperones of heat shock protein family including GRP78,
GRP94 and the co-chaperones; (b) chaperone lectins like caln-
exin, calreticulin and EDEM; and (c) substrate-speciﬁc chaper-
ones such as Hsp47. Additionally, there are at least two groups
of folding catalysts, namely thiol oxidoreductases of the pro-
tein disulﬁde isomerase (PDI) family such as PDI and
GRP58/ERp57 and peptidyl prolyl isomerases (PPIs). There
are two known chaperone systems in the ER, calnexin/calreti-
culin and GRP78/GRP94 [1]. The properties and function of
ER chaperones, co-chaperones and folding enzymes covered
in this review are summarized in Tables 1 and 2.2.1. Calnexin/calreticulin chaperone system
Calnexin is a 90 kDa type I ER membrane protein and
calreticulin is a 60 kDa soluble ER lumen protein with a C-ter-
minal KDEL signal [2,3]. When the newly synthesized poly-
peptides enter the ER, they are often modiﬁed by N-linked
glycans (Glc3Man9GlcNAc2) and the glucoses are rapidly re-
moved by glucosidases I and II [4]. The nascent protein with
monoglucosylated N-linked glycans (Glc1Man9GlcNAc2) is
recognized by the calnexin/calreticulin system for subsequentblished by Elsevier B.V. All rights reserved.
Table 1
Summary of function and disease relevance of ER chaperones, co-chaperones and folding enzymes
Protein Localization Function Knockout mouse model Diseases Reference
GRP78/BiP ER lumen
ER transmembrane
Cell surface
Nucleus
Chaperone,
Ca2+-binding,
ER stress sensor
UPR regulator
Anti-apoptosis
Embryonic lethality at
E3.5 due to failure
of embryo
peri-implantation
Cancer
Alzheimer’s disease
Parkinson’s disease
Prion diseases
Atherosclerosis
[34,57,65,71,75–78,107]
SIL1 ER lumen Co-chaperone,
nucleotide exchange
factor for GRP78
Woozy mouse associated
with cerebellar Purkinje
cell degeneration
and ataxia
Marinesco-Sjo¨gren
syndrome
[58–60]
GRP94/gp96 ER lumen
Cell surface
transmembrane
Chaperone,
Ca2+-binding,
Anti-apoptosis
Tumor immunity
Embryonic lethality Cancer
Prion diseases
Autoimmune
disease
[65,71,86,87,89]
GRP170/ORP150 ER lumen Chaperone,
potential nucleotide
exchange factor for GRP78
Embryonic lethality Alzheimer’s disease [57,61,129]
GRP58/ERp57
ER lumen
Nucleus
Cytosol
Thio-oxidoreductase
to catalyze disulﬁde bond
formation of glycoprotein
Embryonic lethality
(traditional knockout);
Grp58/ B cells are
defective in antigen
presentation (conditional
knockout in B cells)
Prion diseases
Alzheimer’s disease
[35,62,92,130,131]
PDI
ER lumen
Cell surface
Thio-oxidoreductase to
catalyze disulﬁde bond
formation
ND Alzheimer’s disease
Parkinson’s disease
[55,92,132]
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tional and release of the completely folded glycoprotein from
this cycle is usually coupled with transportation from the ER
to the Golgi complex. GRP58/ERp57, a member of the PDI
family, is also an important component involved in the caln-
exin/calreticulin system. It contains two thioredoxin motifs
and acts as a thiol oxidoreductase to catalyze the disulﬁde
bond formations of the loaded glycoproteins [5]. If the glyco-
protein cannot be correctly folded, another ER protein UGGT
(UDP-glucose glycoprotein-glucosyltransferase) recognizes the
unfolded or misfolded glycoprotein and catalyzes the transfer
of a glucose unit from UDP-glucose to a speciﬁc mannose res-
idue within the N-glycan chain of the glycoprotein [6]. Reglu-
cosylation generates the monoglucosylated N-linked glycan
that provides a new binding site of calnexin/calreticulin for
re-entry of the glycoprotein into the cycle, until the correct
folding is achieved [7]. Studies with hydrophobic peptides
and glycoproteins have shown that UGGT recognizes sur-
face-exposed hydrophobic regions [8,9]. While it was reported
that UGGT can sense a local subtle structural alteration gen-
erated by a single point mutation and monoglucosylate glycans
distant from misfolded determinants [10], another study using
RNaseA/B as the substrate found that UGGT only selectively
modiﬁes the N-glycans close to or within the unfolded sites
[11].
2.2. GRP78/GRP94 chaperone system
GRP78, also known as BiP, is the ER homologue of HSP70
proteins with a conserved ATPase domain and a peptide-bind-
ing domain [12,13]. As a chaperone, GRP78 recognizes and
binds to the proteins with hydrophobic residues in the un-
folded regions [14]. Therefore, some calnexin/calreticulin sub-strates can bind to GRP78 if the N-glycosylation is blocked.
GRP78 is in a large multi-protein complex with a set of ER
molecular chaperones, GRP94, PDI, ERp72, GRP170/
ORP150, UGGT, CaBP1 (calcium binding protein), cyclophi-
lin B and SDF2-L1, which forms an ER chaperoning network
processing the unfolded protein substrates [15]. In this com-
plex, GRP94, an ER homologue of HSP90 protein, often func-
tions as a dimer providing a platform for the assembly or
oligomerization of loaded protein cargo [16].3. Regulation of stress signaling by ER chaperones
Cells developed an evolutionarily conserved integrated intra-
cellular signaling cascade, referred to as the UPR, to reduce
the unfolded protein load and increase folding capacity. For
survival, the UPR signals pathways attenuating protein
synthesis, upregulating the transcription of chaperone genes
that increase ER capacity of folding and degradation, and
retro-translocating misfolded proteins to the cytosol for degra-
dation. There are three major UPR pathways with the ER-
resident transmembrane proteins PERK, ATF6 and IRE1 as
proximal signal sensors. Molecular chaperones play regulatory
roles in UPR signaling pathway. The best characterized is the
ER chaperone GRP78 which directly interacts with all three
ER stress sensors, PERK, ATF6 and IRE1, and maintains
them in inactive forms in non-stressed cells [17]. When accu-
mulation of misfolded proteins occurs, GRP78 is titrated
away. Release from GRP78 allows the activation and
transduction of the unfolded protein signals across the ER
membrane to the cytosol and the nucleus. Further character-
ization of post-translational modiﬁcation of the ATF6 reveals
Table 2
Summary of function and disease relevance of ER chaperones, co-chaperones and folding enzymes
Protein Localization Function Knockout mouse model Diseases Reference
Calnexin ER transmembrane
Cell surface
Chaperone,
glycoprotein folding
Postnatal death
and motor disorders
Alzheimer’s disease [46,57,93]
Calreticulin ER lumen
Cytosol
Cell surface
Chaperone,
glycoprotein folding,
Ca2+-binding
Embryonic lethality at
E14.5 due to defective
embryonic cardiac
development
Cardiac hypertrophy
Alzheimer’s disease
Autoimmune diseases
[36,91,131,133,134]
EDEM ER lumen Chaperone, recognition
and targeting of unfolded
glycoprotein for degradation
ND ND [30]
ERp72 ER lumen Thio-oxidoreductase to
catalyze disulﬁde
bond formation
ND ND [135]
Herp ER transmembrane Ubiquitin-like protein
involved in ERAD
ND Atherosclerosis
Alzheimer’s disease
[109,136,137]
P58IPK Cytosol ER membrane Co-chaperone, negative
regulator of eIF2a kinase
PERK and PKR,
cotranslocational degradation
Development of diabetes
associated with increased
b-cell death
Diabetes (mouse) [22,23,25,118,119]
UGGT ER lumen Glucosyltransferase,
recognition of misfolded
glycoprotein and reglucosylation
of N-glycan
Embryonic lethality
at E13
ND [37]
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nal domain of ATF6 can be utilized as novel sensing mecha-
nisms for the activation of the UPR [18,19]. These studies
show that ER stress-induced underglycosylation and reduction
favor the transportation of ATF6 from ER to Golgi and the
cleavage by S1P and S2P to generate the active nuclear form
of ATF6.
For IRE1 signaling, diﬀerent mechanisms have been re-
ported for its activation. A recent study shows that dimeriza-
tion of the cLD region (the core region of luminal domain)
of the yeast IRE1 retains the full function of the IRE1 luminal
domain but is insuﬃcient for the activation, rather the cLD di-
mer presents an MHC-like groove that is proposed to interact
with unfolded proteins and initiate the IRE1 activation [20].
On the other hand, the monomer of the human IRE1a N-ter-
minal luminal domain (NLD) is able to form a dimer that
exhibits an MHC-like groove at the interface [21]. Dimeriza-
tion of the human NLD is able to activate both the kinase
and RNase activities of IRE1a and the MHC-like groove is
too narrow to bind any peptide, implicating that unfolded pro-
tein binding is not required for the activation of IRE1a. There-
fore, the study of human IREa supports the conventional view
that GRP78 is the primary mechanism for regulating IRE1a
activation, whereas the yeast study implies that peptide inter-
action is the key triggering event. Further studies are required
to resolve these apparent diﬀerences.
Another ER stress inducible chaperone, P58IPK, is proposed
to be a negative regulator of PERK activation to inhibit eIF2a
phosphorylation and attenuate the UPR [22]. P58IPK belongs
to the HSP40 family and contains the tetratricopeptide repeats
(TPR) motifs that have been shown to mediate protein-protein
interaction [23]. Therefore, it is considered as a co-chaperone.
Originally, P58IPK was identiﬁed in the cytosol to repress thekinase activity of PKR, the interferon-induced eIF2a kinase,
through the direct association with PKR [24]. Instead of the
cytosolic localization, P58IPK was recently reported to be a
peripheral membrane protein of the rough ER, and in addition
to modifying PERK signaling, P58IPK contributes to ER stress
induced protein degradation through complex formation with
the ER translocon and cytosolic HSP70 chaperone network
[25]. However, more recently, it was determined that P58IPK
contains a functional ER targeting signal consisting of 26
hydrophobic amino acids at the N-terminus (David Ron, per-
sonal communication), implicating that P58IPK may enter the
ER. Thus, the precise orientation of the protein complexes
and how P58IPK facilitates extraction of the stalled proteins
from the ER requires further resolution.4. ER chaperones facilitate ER-associated protein degradation
The ER employs a mechanism termed ER-associated degra-
dation (ERAD) to clear the aggregated misfolded or unassem-
bled proteins. During ERAD, the target proteins selected by
ER quality control system are retrotranslocated to the cytosol
and degraded by the ubiquitin–proteasome system. ER chaper-
ones play key roles in ERAD substrate selection and solubili-
zation [26]. The selection process relies on factors that
primarily recognize substructures within the misfolded pro-
teins such as hydrophobic patches, unpaired cysteines and par-
tially de-mannosylated N-glycans. For example, in the
mammalian calnexin/calreticulin system, the glycoproteins
undergoing futile folding attempts are eventually subject to ter-
minal mannose trimming (from Man9GlcNAc2 to Man8Glc-
NAc2, or extensive trimming to produce Man6GlcNAc2 or
Man5GlcNAc2) [27] by ER a 1, 2-mannosidases, leading to
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teins, and EDEM then targets misfolded mannose trimmed
glycoproteins to degradation [28]. Three EDEM homologues,
EDEM1, EDEM2 and EDEM3, have been identiﬁed and they
are transcriptionally upregulated upon ER stress by the acti-
vated IRE1/Xbp-1 branch [29]. EDEM is required for ERAD
of glycoproteins and overexpression of EDEM1 accelerates the
release of unfolded glycoproteins from calnexin/calreticulin cy-
cle for the onset of degradation [30]. How EDEM delivers sub-
strates to the ER translocon remains to be determined,
however, the association of EDEM with putative components
of the translocon pore (derlins) has recently been reported [31].
In contrast to EDEM, GRP78 with its co-chaperones selects
the ERAD substrates by recognizing the hydrophobic regions
of the polypeptides that are usually exposed on the surface of
misfolded or unassembled proteins. Simultaneously, they also
retain the terminally misfolded proteins in soluble conforma-
tions preventing their aggregation in the ER lumen. Appar-
ently all known soluble ERAD substrates require GRP78
and co-chaperones for their degradation [26,32]. After release
from GRP78 in an ATP-dependent manner, the targeted mis-
folded proteins are sorted to the ERAD pathway. PDI is also
known as a chaperone that plays a role in ERAD, in addition
to its enzymatic activities. PDI has been shown to speciﬁcally
interact with disulﬁde-free, misfolded secretory proteins in
yeast and target them to the Sec61 translocon for degradation
[33].5. ER chaperone function is obligatory for early mammalian
development
Gene knockout technology allows deﬁnitive tests for the
requirement of speciﬁc ER chaperone function in vivo. Tradi-
tional knockout approach creating homozygous deletion of
ER chaperones such as GRP78 [34], GRP94 (Mao and Lee,
in preparation), GRP58/ERp57 [35], calreticulin [36] and
UGGT [37] results in embryonic lethality. The phenotypes of
mouse knockout models of the ER chaperones, co-chaperones
and folding enzymes covered in this review are summarized in
Tables 1 and 2. These studies provide direct evidence that the
function of each of these ER chaperones cannot be compen-
sated during mouse development. Thus, heterozygous mutants
and/or tissue-speciﬁc knockout mouse models are required to
elucidate the critical contribution of these chaperones in mam-
malian development.
For GRP78, it has recently been shown that complete deple-
tion of GRP78 leads to lethality in 3.5-day-old embryos (E3.5)
due to the failure of embryo peri-implantation [34]. The
Grp78/ embryos cannot hatch from the zona pellucida
in vitro, fail to grow in culture, and exhibit proliferation de-
fects and a massive increase of apoptosis in the inner cell mass,
which are precursors of embryonic stem cells. These ﬁndings
show that GRP78 is essential for embryonic cell growth and
pluripotent cell survival. In another study, transgenic mouse
lines bearing a lacZ reporter gene driven by 3 kb of the rat
GRP78 promoter or a mutant promoter with ER stress-re-
sponse element (ERSE) deletion were used to evaluate the
transcriptional regulation of GRP78 during mouse embryonic
development. GRP78 is transcriptionally upregulated in both
the trophectoderm and inner cell mass of E3.5 embryos and
this induction is largely dependent on the ERSE. Since ERSEis an essential cis-element of the Grp78 promoter for induction
by ER stress, this suggests that physiological ER stress may ex-
ist at the peri-implantation stage of early development due to
the increased activity of cell proliferation and protein secre-
tion. On the other hand, Grp78+/ mice are viable and compa-
rable to wild-type although GRP78 level in the heterozgyotes
is about 50% of the wild-type siblings. The GRP94 and PDI
levels are mildly elevated in the Grp78+/ mice, whereas the
levels of the other two ER chaperones, calnexin and calreticu-
lin, are not aﬀected. Thus, during normal mouse development,
50% of wild-type GRP78 level is apparently suﬃcient to main-
tain ER homeostasis. This is consistent with the view that com-
pared to normal tissues and organs, GRP78 is more critically
needed in cells undergoing physiological or pathological stress.
Embryonic lethality was also observed in the GRP58/ERp57
knockout mice whereas the conditional knockout mice with
GRP58/ERp57 deﬁciency in B cells are viable [35]. The devel-
opment and proliferation of GRP58/ERp57 deﬁcient B cells
are normal, but the MHC class I antigen presentation is im-
paired. During biosynthesis, MHC class I heavy chain is pro-
cessed in the calnexin/calreticulin system where GRP58/ERp57
participates in oxidative folding by catalyzing disulﬁde bond
formation and isomerization [38]. GRP58/ERp57 is also de-
tected in the peptide-loading complex consisting of TAP1/
TAP2, the MHC class I-speciﬁc chaperone tapasin, calreticu-
lin, GRP58/ERp57 and MHC I heterodimers [39], implicating
that GRP58/ERp57 plays a role in loading of peptides onto
MHC class I molecules. In the GRP58/ERp57-deﬁcient B cells,
the amount of cell surface MHC class I-peptide complexes and
the peptide loading complex-associated MHC class I are dra-
matically decreased compared with the wild-type B cells and
the dissociation of MHC class I from the complex is much fas-
ter. These observations indicate that GRP58/ERp57 recruits
MHC class I to the peptide-loading complex and maintains
the peptide-MHC I complex in a steady state. In addition,
GRP58/ERp57 deﬁciency in B cells also aﬀects the recruitment
of calreticulin into the loading complex [35]. Thus, MHC class
I antigen presentation ability is diminished by the deﬁciency of
GRP58/ERp57 in B cells due to the impaired peptide-loading
machinery.
Calreticulin deﬁciency is lethal in mouse embryos at E14.5,
resulting from a lesion in cardiac development [36]. The ven-
tricular wall made of cardiomyocytes became thinner in the
heart of calreticulin/ mouse embryos. Calreticulin is highly
expressed in cardiomyocytes at the early stage of heart devel-
opment and downregulated after birth in the healthy mature
heart. Interestingly, GRP78 and GRP94 are also upregulated
during embryonic cardiac development indicating that some
ER chaperones may be essential for cardiogenesis [40–43]. In
calreticulin-null ﬁbroblast, the Ca2+ storage capacity of the
ER is reduced [44], whereas overexpression of calreticulin in-
creases the ER Ca2+ level [45]. Since Ca2+ enhances the cli-
ent-binding and chaperoning ability of ER chaperones,
changes in the ER Ca2+ storage capacity or impairment of
Ca2+ binding to these chaperones aﬀect the quality of ER pro-
tein folding and assembly.
Calnexin is another major component of the calnexin/calret-
iculin chaperone system. Interestingly, calnexin deﬁcient mice
are viable, but 50% of the calnexin/ mice died within 2 days
of birth and the surviving mice are smaller than the littermates
and exhibit obvious motor disorders [46]. The calnexin/ mice
are further characterized by a dramatic loss of large to medium
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atic nerve, implying that calnexin plays a tissue-speciﬁc role in
mammalian physiology. Furthermore, deletions of calnexin,
calreticulin and GRP58/ERp57 have very speciﬁc conse-
quences on glycoprotein maturation. For example, defective
maturation of MHC class I in cells lacking calreticulin [47],
of inﬂuenza virus hemagglutinin in cells lacking calnexin [48]
or ERp57 [49] and of a series of heavily glycosylated proteins
sharing common structural domains in cells lacking ERp57
[50] have been reported.6. ER chaperones ameliorate protein misfolding in
neurodegenerative diseases
Neurodegenerative diseases such as Parkinson’s disease and
Alzheimer’s disease are pathologically characterized by the
intracellular or extracellular accumulation of misfolded pro-
teins or mutated gene products [51]. Thus, occurrences of
ER stress and UPR activation have been observed in the af-
fected neuronal cells [52]. Mounting evidence suggests that
ER chaperones are highly induced to ameliorate the accumula-
tion of misfolded proteins and protect neuronal cells against
neurotoxicity [53,54]. Impairment of the functions of the in-
volved chaperones leads to the failure of attenuating ER stress
and eventual apoptosis of neuronal cells. This is supported by
the development of neurological disorders in knockout mouse
models of ER chaperones and co-chaperones as summarized in
Tables 1 and 2.
S-nitrosylated PDI was found in the brain samples of Parkin-
son’s or Alzheimer’s patients and exposure of the cultured neu-
rons to NMDA that induced Ca2+ inﬂux and nitric oxide
production also resulted in S-nitrosylation of PDI [55]. PDI
catalyzes thio-disulﬁde exchange facilitating the disulﬁde bond
formation and rearrangement reaction. In response to ER
stress, PDI is usually upregulated and protects neuronal cells
against ischemic injury [56]. S-nitrosylation of PDI inhibits its
enzymatic activity and leads to the accumulation of polyubiq-
uitinated proteins and activation of UPR. On the other hand,
overexpression of wild-type PDI attenuates UPR and protects
cells against apoptosis induced by ER stress inducers such as
tunicamycin which inhibits N-linked protein glycosylation
and thapsigargin which is an inhibitor of ER Ca2+-ATPase [55].
Overexpression of GRP78, calnexin and GRP170/ORP150
suppressed the production of b-amyloid peptides (Ab), a major
component of extracellular senile plaques in Alzheimer’s dis-
ease [57]. Further, co-immunoprecipitation identiﬁed the asso-
ciation of amyloid precursor protein (APP) with GRP78,
suggesting that GRP78 overexpression inhibits APP matura-
tion through retention of APP in the ER and thus reduces
the Ab production by proteolysis of APP. The protective role
of GRP78 in neurodegeneration is supported by the studies of
woozy mutant mice and Marinesco-Sjo¨gren syndrome (MS)
patients. Human MS syndrome is a rare disease associated
with cerebellar ataxia, progressive myopathy and cataracts.
Recently, mutations of SIL1, an adenine nucleotide exchange
factor of GRP78, have been identiﬁed to cause the MS syn-
drome [58,59]. Further, in vivo study with the SIL1 mutant
woozy mouse model revealed that loss of functional SIL1 re-
sults in cerebellar Purkinje cell degeneration and ataxia [60].
SIL1 stimulates the release of ADP from GRP78, activating
the ATPase cycle to promote the binding and folding of thesubstrate proteins. It was observed that ubiquitinated proteins
aggregate in the ER and cytosol and the UPR pathway is acti-
vated to upregulate GRP78, GRP170/ORP150 and CHOP in
response to the ER stress induced in cerebellar Purkinje cells.
It is noted that the cerebellum is particularly sensitive to loss
of SIL1 function, and within the cerebellum only some lobules
have degenerated Purkinje cells. One possible explanation for
this observation is that other co-chaperone(s) can compensate
for SIL1 function in the unaﬀected cerebellar lobules.
GRP170/ORP150 has recently been implicated to substitute
for SIL1 as an alternative nucleotide exchange factor for
GRP78 in an in vitro experimental system [61]. Thus, in diﬀer-
ent tissues or in diﬀerent regions of speciﬁc tissues, the distri-
bution and activity of various co-chaperones could vary,
giving rise to distinct phenotypes.
GRP58/ERp57 has been implicated in prion diseases, be-
cause it is consistently upregulated in the prion replicating
brain areas of the scrapie prion-infected mice and its overex-
pression protects neuronal cells against PrPsc toxicity and ER
stress-induced apoptosis [62,63]. Prion diseases, also known
as transmissible spongiform encephalopathies (TSEs) are fatal
neurodegenerative disorders characterized by accumulation of
the misfolded form of the cellular prion protein (PrP), denoted
PrPsc (scrapie-associated PrP), and consequent neuronal dys-
function and death [64]. The conformational changes of PrPsc
lead to the generation of the protease-resistant and insoluble
form of the prion protein, which is believed to be neurotoxic.
ER stress resulting from PrPsc aggregation induces the apopto-
sis of neuron cells [65]. The upregulation of ER stress chaper-
ones, such as GRP78, GRP94 and GRP58/ERp57, was also
observed in PrPsc-infected neuroblastoma cells [65] and the cor-
tex samples of TSEs patients [64]. Furthermore, GRP58/ERp57
was found to interact with PrPsc and this interaction was en-
hanced when cells were infected with scrapie prion or treated
with proteasome inhibitor, suggesting that GRP58/ERp57
selectively binds to PrPsc [62]. Since GRP58/ERp57 is a thiol
oxidoreductase to catalyze disulﬁde bond formation, it is possi-
ble that the interaction of GRP58/ERp57 enhances correct
folding of PrP and thus reduces the PrPsc neurotoxicity. Fur-
thermore, a recent study reveals that ER stress facilitates the
generation of a misfolded PrP isoform that is more prone to
be eﬃciently converted into PrPsc and that ER damaged cells
might be more susceptible to prion replication, contributing
to rapid progression of prion disease [66].7. ER chaperones promote cancer progression and tumor
immunity
Due to hypoxic conditions and glucose deprivation caused
by poor vascularization, the microenvironment of tumors rep-
resents physiological ER stress and the UPR is activated for
the survival of tumor cells [67,68]. ER chaperones serve as a
novel class of pro-survival components protecting the host
against death induced by ER stress when expressed at high
levels. In cell culture systems, it has been established that
GRP78 [69,70], GRP94 [71], calreticulin [72] and the homo-
cysteine-induced endoplasmic reticulum protein, Herp [73]
protect cancer cells against ER stress-induced apoptosis.
Among them, GRP78 is best-characterized with respect to its
role in cancer progression, drug resistance and possibly metas-
tasis [74, Table 1].
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by antisense were either unable to form tumors or quickly re-
gressed [69], implying that GRP78 is required for tumor
growth. Recent investigations using mouse knockout models
reaﬃrmed the important role of GRP78 in tumor development
and progression (Dong and Lee, in preparation). GRP78
expression is highly upregulated in varieties of cancer cell lines
and human cancer specimens, including breast cancer, lung
cancer, liver cancer and prostate cancer, correlating with
malignancy, metastasis and drug resistance [75]. In a variety
of human cancers, GRP78 upregulation protects tumor cells
from chemotherapeutic agents and knockdown of GRP78 with
siRNA or antisense sensitizes these cells to those agents
[75,76]. GRP78 protects cancer cells through multiple mecha-
nisms. Under glucose starvation and severe hypoxic conditions
in solid tumors, GRP78 is induced by activated UPR signaling
to ameliorate misfolded protein aggregation in the ER.
Through its ability to bind Ca2+, GRP78 serves as a buﬀering
agent in the ER, preventing Ca2+ eﬄux from the ER to the
cytosol and alleviating the ER stress-induced apoptotic stim-
uli. Furthermore, the cytoprotective role of GRP78 also attri-
butes to its inhibition of the activation of pro-apoptotic
components, such as BIK and BAX, as well as suppressing
the cleavage of procaspase-7 and procaspase-12 through com-
plex formation [77–79]. Since a subfraction of GRP78 exists as
an ER transmembrane protein with the amino portion in the
cytosol, it can potentially directly interact with pro-apoptotic
components such as BIK, BAX, caspase-12 and caspase-7
which are known to be localized to the ER [75,78,79]. It is also
possible that GRP78 in the lumen of the ER complexes with
ER-transmembrane proteins that interact with the cytosolic
pro-apoptotic components. Since BIK, BAX and caspase-7
are activated by a variety of chemotherapeutic regimens, inhi-
bition of their activation by GRP78 may confer general che-
mo-resistance to cancer cells [75]. Additionally, BIK is
required for estrogen-starvation induced apoptosis in estrogen
receptor positive human breast cancer cells and its apoptotic
activity is blocked by GRP78 in human breast cancer cells
[79,80]. BIK is a BH3-only protein of the BCL-2 family and
plays a pro-apoptotic role through regulating the oligomeriza-
tion of BAX and BAK in the mitochondrial outer membrane
and release of mitochondrial cytochrome c. BIK is known to
inhibit Bcl-2 activity by direct association. Therefore, inhibi-
tion of BIK by GRP78 in human breast cancer could lead to
resistance to chemotherapy as well as anti-estrogen therapy.
In retrospective studies, GRP78 level in patient tumor speci-
mens has been shown to associate with poor survival, resis-
tance to adriamcyin therapy in breast cancer patients [81,82]
and recurrence in prostate cancer patients [83,84]. Thus,
GRP78 is a potential novel biomarker for tumor behavior
and development of resistance to therapy in cancer [74].
GRP94, the ER homologue of HSP90 also referred to
as gp96, shares common transcriptional regulatory elements
with the GRP78 promoter and is coordinately regulated with
GRP78 [85]. Induction of GRP94 is commonly associated with
upregulation of GRP78 in the tumor samples and cell lines.
Overexpression of GRP94 is correlated with cellular transfor-
mation, tumorigenicity and decreased sensitivity to X-rays in
cancer cell lines, whereas decrease of GRP94 level by antisense
results in the enhanced sensitivity of tumor cells to etoposide
treatment [71]. Interestingly, etoposide-induced cell death trig-
gers proteolytic cleavage of GRP94 by calpain, which alsocleaves Bcl-xL during apoptosis, therefore converting a pro-
survival protein into a pro-apoptotic molecule [86]. In addi-
tion, the role of GRP94 in cancer has been widely recognized
due to its ability to induce a tumor-speciﬁc protective immu-
nity in various experimental tumor models (Table 1). GRP94
is found to associate with diverse peptides including tumor-
speciﬁc antigens in the ER and the complexes are captured
by antigen-presenting cells, which in turn present the peptides
to MHC class I complex leading to the cell-mediated immune
response [87]. Based on this mechanism, GRP94 vaccines have
been extensively developed in cancer therapy. The isolated
GRP94-peptide complexes from speciﬁc cancer tissues or mod-
iﬁed cancer cell lines are currently used as vaccines to immu-
nize animal tumor models or patients in clinical trials. The
studies observed that the immunization elicits the speciﬁc im-
mune response and tumor regression and the eﬃciency is im-
proved by low dose of cyclophosphamide, an inhibitor of the
induction of suppressive regulatory T cells [88]. Cell surface
GRP94 has also been implicated in systemic autoimmune dis-
eases [89].
Cell surface localization of GRP78, PDI, calnexin and cal-
reticulin have been reported [90–93]. In prostate cancer cells,
GRP78 serves as a receptor for activated macroglobulin and
is postulated to promote proliferation, survival and cell motil-
ity [94,95]. Cell surface expression of GRP78 in tumors but not
in normal organs has prompted new directions in targeting
cytotoxic agents into cancer cells [71,74,90].8. ER chaperones alleviate atherosclerosis stress
Atherosclerosis is a chronic and progressive disease physio-
logically characterized by the hardening and narrowing of
the arteries due to the formation of atheromatous plaques on
the inside walls of arteries. It is well-established that athero-
sclerosis is a principle cause of cardiovascular disease, such
as atherothrombotic disease, myocardial infarction, stroke,
etc. [96,97]. Numerous clinical and epidemiology studies have
demonstrated that hyperhomocysteinemia (HHcy) is an inde-
pendent risk factor for atherosclerosis and thrombotic disease
[98,99]. Deﬁciencies in homocysteine metabolism, such as
nutritional deﬁciencies in B vitamin cofactors or mutations
in cystathionine b-synthase (CBS) gene or 5,10-methylenetetra-
hydrofolate reductase (MTHFR), can lead to hyperhomocy-
steinemia or even a severe form of HHcy, homocystinuria
[100]. Studies on the potential cellular mechanism by which
homocysteine promotes atherosclerosis revealed that HHcy in-
duces activation of proinﬂammatory factors [101–103], oxida-
tive stress [104] and ER stress associated with activation of the
UPR [105,106]. As summarized in Tables 1 and 2, increased
expression of ER stress response genes including GRP78,
GRP94, Herp and RTP (reducing agents and tunicamycin-
responsive protein) has been observed as a consequence of
high levels of intracellular homocysteine [107–109]. Homocys-
teine-induced ER stress leads to overexpression of pro-apopto-
tic factors including GADD153/CHOP and TDAG51 (T cell
death-associated gene 51) and activation of caspase-3
[108,110–112], which contributes to HHcy-associated vascular
endothelial cell injury that may promote the development of
atherothrombotic diseases. In addition, homocysteine-induced
ER stress also induces the expression of the sterol regulatory
element-binding proteins (SREBPs) in hepatocytes, vascular
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resident transcription factors responsible for the activation of
genes involved in the cholesterol and triglyceride biosynthesis
pathways. Increased expression of SREBPs is also associated
with intracellular accumulation of cholesterol. Stable overex-
pression of GRP78 is able to inhibit the activation of SREBPs
and the genes under their regulation [113], which implies that
GRP78 may be a potential factor to inhibit atherosclerosis.
Further, GRP78 was discovered to suppress thrombin genera-
tion by inhibiting tissue factor (TF) procoagulant activity
[114], whereas homocysteine induces TF procoagulant acti-
vity. TF is a transmembrane glycoprotein and plays a role in
initiation of the extrinsic coagulation cascade and increased
expression of TF has been detected in atherosclerotic pla-
ques [115]. Thus, increased level of ER chaperone GRP78
can potentially suppress the development or progression of
hyperhomocysteinemia and atherosclerosis through: (i) allevi-
ating the homocysteine-induced ER stress; (ii) preventing
apoptosis of vascular endothelial cells; (iii) inhibiting the
activation of genes responsible for cholesterol/triglyceride bio-
synthesis; and (iv) suppressing the procoagulant potential of
cells.9. Link of diabetes to UPR pathways and ER chaperone function
Diabetes is a prevalent metabolic disease characterized by
perturbed glucose metabolism. Usually, this disease is initiated
by failure of pancreatic b-cells associated with autoimmunity
(type 1) or insulin resistance in peripheral tissues (type 2). De-
fects in speciﬁc UPR pathways have been linked to diabetes in
mouse models and humans. One example is the human Wol-
cott-Rallison syndrome, a rare autosomal-recessive disorder
associated with pancreatic b-cell death and infancy-onset dia-
betes [116]. PERK mutations resulting in truncated or dysfunc-
tional PERK protein are responsible for this disorder. Similar
defect was also observed in Perk/ mice and increased b-cell
apoptosis has been detected in the mouse islets [117]. The acti-
vation of PERK upon ER stress involves dissociation from
GRP78, oligomerization of PERK and autophosphorylation
of serine/threonine kinase domain. The activated PERK fur-
ther phosphorylates eIF2a (a subunit of translational initia-
tion factor), which results in transient inhibition of global
translation, thereby preventing further protein accumulation
in the ER and suppressing ER stress-induced cell death [17].
Therefore, PERK is a crucial pathway in pancreatic b-cells
to attenuate the stress signaling for survival.
The link of molecular chaperones to diabetes is just emerg-
ing. A recent study suggests that deﬁciency of P58IPK, an
inhibitor of PERK activation, causes type 1 diabetes and
late-stage type 2 diabetes in mice associated with hyperglyce-
mia and hypoinsulinemia concomitant with increasing apopto-
sis of pancreatic islet b-cells [118]. Deﬁciency of P58IPK has no
eﬀect on the insulin secretion by viable pancreatic b-cells and
insulin sensitivity of peripheral tissues. However, the adult
P58IPK/ mice with hyperglycemia showed increased b-cell
death and upregulation of pro-apoptotic genes, suggesting that
loss of functional pancreatic b-cells leads to hypoinsulinemia
and subsequent high blood glucose level. Although P58IPK is
a known inhibitor of both PERK and the cytosolic eIF2a ki-
nase PKR, its depletion only activates PERK, but not PKR
[119]. The diabetic phenotypes of P58IPK/ mice showed thatsustained activation of PERK could lead to prolonged ER
stress and induce apoptosis of pancreatic b-cells (Table 2).
As a downstream eﬀector of PERK, the heterozygous loss-
of-function mutation of eIF2a in mice fed on high fat diet re-
sults in development of diabetes and obesity [120]. This muta-
tion substitutes alanine at Ser51, the phosphorylation site of
eIF2a by PERK or PKR for translational inhibition. This dia-
betes mouse model is characterized by glucose intolerance,
abnormal ER distension and inadequate insulin secretion in
b-cells. Further, in eIF2a mutant mice fed with high fat diet,
increased amount of proinsulin was associated with GRP78
and production of mature insulin was decreased, suggesting
that the stable association with GRP78 inhibits the processing
of proinsulin into mature insulin. Thus, the S/A mutation of
eIF2a abolishes the ability of b-cells to adapt to ER stress
through translational attenuation in the high-fat diet fed mice.
The increased expression of proinsulin exceeds the folding
capacity of the ER and GRP78 retains the proinsulin mole-
cules in the ER for further folding process or degradation
through ERAD, which contributes to the reduced insulin level
in islets and diabetic symptoms.10. ER chaperones and bacterial pathogenesis
Bacterial toxins are major determinants of bacterial viru-
lence and even lethality and the main causes of human diseases
in bacteria-infected populations. Generally, there are two types
of bacterial toxins, lipopolysaccharides, which are associated
with the cell walls of gram-negative bacteria, and proteins,
which are typically soluble proteins acting as enzymes intracel-
lularly or extracellularly. Bacterial protein toxins usually con-
tain two components: A subunit possesses enzymatic activity
and B subunit provides binding to the speciﬁc cell surface
receptor. In general, toxins bound to the cell surface receptor
are endocytosed, and transported retrogradely to the Golgi
and the ER as a holotoxin. When released from the AB native
toxin, the enzymatic A subunit becomes active. Evidence indi-
cated that PDI mediates the disassembly of cholera toxin (CT)
holotoxin [121]. CT has a typical AB5 arrangement of protein
toxins, which contains ﬁve B subunits and a single A subunit
that is cleaved into A1 catalytic chain and A2 chain upon
secretion. When CT holotoxin is taken up by intestinal
cells and translocated into the ER, the reduced form of ER
chaperone PDI binds to the A1 chain, reduces the disulﬁde
bridge between the A1 and A2 chains [122], and releases the
A1 chain from the holotoxin when the C-terminal disulﬁde
bond of PDI is oxidized by endoplasmic reticulum oxidoreduc-
tin 1 (Ero1) [123]. Eventually, the A1 chain is transferred
across the ER membrane to the cytosol where it refolds into
an active enzyme that ADP-ribosylates a trimeric G protein
and in turn activates adenylyl cyclase to elevate cAMP level
for activation of chloride channels at the cellular plasma
membrane, which leads to diarrhea. Thus, the unfolding pro-
cess by PDI facilitates the retrotranslocation of the A1 chain
of CT. However, other PDI family members modify toxin ret-
rotranslocation diﬀerently. A recent study revealed that
ERp72, a PDI-like protein retains the A1 chain of CT in the
ER and may potentially reduce the cytosolic activated A1
chain [124].
Another interesting discovery is that a bacterial toxin,
named AB5 subtilase cytotoxin (SubAB), causes cell lethality
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thus inactivating GRP78 function [125]. SubAB has been de-
tected in a virulent strain of Shiga toxigenic Escherichia coli
(STEC) and several other STEC serotypes. The STEC strains
are known to produce Shiga toxins that have been found to
cause the recent US outbreak of E. coli from fresh spinach
and cause haemolytic uraemic syndrome in humans [126].
The A subunit of Shiga toxin is exported from the ER lumen
to the cytosol, where it enzymatically cleaves the 28S rRNA
resulting in inhibition of protein synthesis and death of host
cells [127]. In contrast, the A subunit of SubAB remains in
the ER lumen instead of being retrotranslocated to the cytosol
and cleaves GRP78 at the region linking the ATPase domain
and the peptide-binding domain, thus destroying the cytopro-
tective GRP78 and leading to cell death. Therefore, STEC
strains bearing SubAB are expected to pose serious threat to
human health. On the other hand, SubAB may be a potential
tool in medical application regarding to its function of specif-
ically eliminating GRP78, since induction of GRP78 expres-
sion is correlated with tumor growth and drug resistance in a
variety of human cancers [128].
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